Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Changes in gene transcription underlying the aberrant citrate and choline metabolism in human prostate cancer samples.

Bertilsson H, Tessem MB, Flatberg A, Viset T, Gribbestad I, Angelsen A, Halgunset J.

Clin Cancer Res. 2012 Jun 15;18(12):3261-9. doi: 10.1158/1078-0432.CCR-11-2929. Epub 2012 Apr 17.

2.

Spermine and citrate as metabolic biomarkers for assessing prostate cancer aggressiveness.

Giskeødegård GF, Bertilsson H, Selnæs KM, Wright AJ, Bathen TF, Viset T, Halgunset J, Angelsen A, Gribbestad IS, Tessem MB.

PLoS One. 2013 Apr 23;8(4):e62375. doi: 10.1371/journal.pone.0062375. Print 2013.

3.

Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.

Selnaes KM, Gribbestad IS, Bertilsson H, Wright A, Angelsen A, Heerschap A, Tessem MB.

NMR Biomed. 2013 May;26(5):600-6. doi: 10.1002/nbm.2901. Epub 2012 Dec 27.

PMID:
23280546
4.

Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues.

Singh KK, Desouki MM, Franklin RB, Costello LC.

Mol Cancer. 2006 Apr 4;5:14.

5.

Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13. doi: 10.1016/j.ijrobp.2011.03.008. Epub 2011 May 24.

PMID:
21605949
6.

Two-dimensional spectroscopic imaging for pretreatment evaluation of prostate cancer: comparison with the step-section histology after radical prostatectomy.

Weis J, Ahlström H, Hlavcak P, Häggman M, Ortiz-Nieto F, Bergman A.

Magn Reson Imaging. 2009 Jan;27(1):87-93. doi: 10.1016/j.mri.2008.05.010. Epub 2008 Jul 3.

PMID:
18599244
7.

Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G.

Radiol Med. 2008 Aug;113(5):670-88. doi: 10.1007/s11547-008-0271-8. Epub 2008 May 20. English, Italian.

PMID:
18493829
9.

Metabolic, pathologic, and genetic analysis of prostate tissues: quantitative evaluation of histopathologic and mRNA integrity after HR-MAS spectroscopy.

Santos CF, Kurhanewicz J, Tabatabai ZL, Simko JP, Keshari KR, Gbegnon A, Santos RD, Federman S, Shinohara K, Carroll PR, Haqq CM, Swanson MG.

NMR Biomed. 2010 May;23(4):391-8. doi: 10.1002/nbm.1474. Epub 2009 Dec 23.

10.

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.

11.

Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues.

Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, James JK, Hurd RE, Kurhanewicz J.

Magn Reson Med. 2003 Nov;50(5):944-54.

12.

Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism.

Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, Jones DJ, Wilson ID, Farmer PB, Steward WP, Gant TW, Gescher AJ, Keun HC.

Prostate. 2008 Jul 1;68(10):1035-47. doi: 10.1002/pros.20761.

PMID:
18459103
13.

Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.

Zbýň Š, Krššák M, Memarsadeghi M, Gholami B, Haitel A, Weber M, Helbich TH, Trattnig S, Moser E, Gruber S.

Rofo. 2014 Jul;186(7):698-702. doi: 10.1055/s-0033-1356359. Epub 2014 Jun 18.

PMID:
24940925
14.

Bioenergetic theory of prostate malignancy.

Costello LC, Franklin RB.

Prostate. 1994 Sep;25(3):162-6.

PMID:
7520580
15.

MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.

Hasumi M, Suzuki K, Oya N, Ito K, Kurokawa K, Fukabori Y, Yamanaka H.

Anticancer Res. 2002 Mar-Apr;22(2B):1205-8.

PMID:
12168926
16.

Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.

Kurhanewicz J, Vigneron DB, Hricak H, Parivar F, Nelson SJ, Shinohara K, Carroll PR.

Radiology. 1996 Aug;200(2):489-96.

PMID:
8685346
17.

Proton MR spectroscopy of the prostate.

Mueller-Lisse UG, Scherr MK.

Eur J Radiol. 2007 Sep;63(3):351-60. Epub 2007 Aug 20. Review.

PMID:
17709223
18.

Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: status of endogenous citrate and dependence on aconitase and fatty acid synthase.

Mycielska ME, Broke-Smith TP, Palmer CP, Beckerman R, Nastos T, Erguler K, Djamgoz MB.

Int J Biochem Cell Biol. 2006;38(10):1766-77. Epub 2006 May 9.

PMID:
16798056
19.

High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies.

van Asten JJ, Cuijpers V, Hulsbergen-van de Kaa C, Soede-Huijbregts C, Witjes JA, Verhofstad A, Heerschap A.

MAGMA. 2008 Nov;21(6):435-42. doi: 10.1007/s10334-008-0156-9. Epub 2008 Nov 25.

PMID:
19031091
20.

Supplemental Content

Support Center